Role of B-Type Monoamine Oxidase Inhibition in the Treatment of Parkinson’s Disease

1986 ◽  
pp. 53-81 ◽  
Author(s):  
Joseph Knoll
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition

The evolving role of monoamine oxidase inhibitors in the treatment of Parkinson's disease

Neurology ◽  
2004 ◽  
Vol 63 (Issue 7, Supplement 2) ◽  
pp. S1-S1
Author(s):  
W. C. Koller ◽  
M. B. Stern ◽  
R. Watts
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibitors

scholarly journals A szelektív monoaminoxidáz-B-gátlók helye a Parkinson-kór kezelési stratégiájában a marosvásárhelyi ideggyógyászati klinikák gyakorlatában

2017 ◽  
Vol 158 (51) ◽  
pp. 2023-2028
Author(s):  
József Attila Szász ◽  
Viorelia Constantin ◽  
Péter Alpár Fazakas ◽  
Eszter Blényesi ◽  
Levente Gábor Grieb ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Dopamine Agonists ◽  
Disease Duration ◽  
Monoamine Oxidase Inhibitors ◽  
Monoamine Oxidase B ◽  
Advanced Stages ◽  
Therapeutic Recommendations

Abstract: Introduction: Selective monoamine oxidase B inhibitors have an accurate place in therapeutical strategy of Parkinsons’s disease. In the early stages of the disease, especially in younger patients with milder symptoms, the introduction of levodopa substitution could be efficacious in delaying; in advanced stages they are mainly used to treat motor complications, as an adjunct to levodopa. Aim: The evaluation of therapeutical strategies used in the neurology clinics of Tirgu Mures County Emergency Clinical Hospital in order to define the role of monoamine oxidase B inhibitors. Method: This retrospective study includes all records of patients with Parkinson’s disease hospitalized between 1 January 2003 and 31 December 2016. From the 2194 reports we used data focusing on the therapeutic recommendations. Regarding disease duration, we divided the patients in two groups: less than or equal to 5 years and more than 5 years. Results: From the 1183 patients in first group, 243 received monoamine oxidase inhibitors: 12 as monotherapy, 52 together with dopamine agonists, in 61 cases combined with levodopa. In 118 cases monoamine oxidase inhibitors were combined with levodopa and dopamine agonists. From 582 cases whith Parkinson’s disease for more than 5 years, 195 received monoamine oxidase B inhibitors (selegiline: 10 cases, rasagiline: 185 cases). In 429 cases we did not find accurate data regarding disease duration (selegiline: 5 cases, rasagiline: 93 cases). Conclusion: The use of monoamine oxidase B inhibitors was similar to those found in literature. The treating physicians should utilise more confidently the available therapeutical combinations. Orv Hetil. 2017; 158(51): 2023–2028.

The Role of Monoamine Oxidase B Inhibitors in the Treatment of Parkinson’s Disease – An Update

2021 ◽  
Vol 21 ◽  
Author(s):  
Zhi Xin Chew ◽  
Chooi Ling Lim ◽  
Khuen Yen Ng ◽  
Soi Moi Chye ◽  
Anna Pick Kiong Ling ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Neuropsychiatric Symptoms ◽  
European Medicines Agency ◽  
Dopamine Level ◽  
Mao B ◽  
Sensory Disturbances ◽  
Non Motor Symptoms

Abstract: Parkinson's disease (PD) is a progressive neurodegenerative disease characterised by reduced dopamine level in the substantial nigra. This may lead to typical motor features such as bradykinesia, resting tremors and rigid muscles; as well as non-motor symptoms such as neuropsychiatric symptoms, sleep disorders, autonomic dysfunction, and sensory disturbances. Inhibitors of MAO-B are used to alleviate symptoms by reducing monoamine oxidase-catalysed degradation of dopamine; hence, preserving functional levels of dopamine. The very first MAO-B used therapeutically was selegiline, followed by rasagiline, its indane derivative which has superior efficacy and selectivity. Both inhibitors can be used as monotherapy or in combination with other anti-Parkinson drugs. Safinamide, a reversible MAO-B inhibitor that utilises both dopaminergic and non-dopaminergic mechanisms, was recently approved by the European Medicines Agency (EMA) (2015) and U.S. FDA (2017) as an add-on therapy for patients with mid- or late-stage Parkinson’s disease. Furthermore, MAO-B inhibitors were found to be associated with potential neuroprotective and disease modifying effects. However, evidence of their efficacy and role in PD models are scarce and warrants further investigation.

Role of Monoamine Oxidase Inhibition and Monoamine Depletion in Fenfluramine-Induced Neurotoxicity and Serotonin Release

2001 ◽  
Vol 89 (5) ◽  
pp. 237-248 ◽  
Author(s):  
Alycia K. Halladay ◽  
Emily Kirschner ◽  
Kelly Hesse ◽  
Hans Fisher ◽  
George C. Wagner
Keyword(s):  
Monoamine Oxidase ◽  
Serotonin Release ◽  
Monoamine Oxidase Inhibition ◽  
Oxidase Inhibition ◽  
Monoamine Depletion

A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease

Neurology ◽  
2004 ◽  
Vol 63 (Issue 7, Supplement 2) ◽  
pp. S32-S35 ◽  
Author(s):  
M. B.H. Youdim ◽  
P. F. Riederer
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Monoamine Oxidase Inhibitors
Sign in / Sign up

Export Citation Format

Share Document